SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is currently experiencing significant momentum and volatility driven by its specialized memory technology, which is increasingly viewed as a critical component for AI, data centers, and defense applications. The community is heavily focused on the stock's potential as a 'hidden gem' with a low float, with many participants actively debating whether this is the start of a parabolic squeeze or a speculative bubble.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is generating significant community buzz as investors highlight its potential as a sovereign, decentralized cloud infrastructure alternative to Big Tech. While the community is actively debating the impact of upcoming tokenomics shifts and mission-driven network upgrades, momentum-focused traders are closely watching price action and accumulation levels in a high-volatility market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and retail accumulation, driven by trader enthusiasm for its data-focused ecosystem and Japanese blockchain initiatives. Community members are actively debating the token's technical breakout potential while monitoring its correlation with broader crypto market trends and ongoing speculation regarding ecosystem expansion.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is surging as a primary beneficiary of record earnings, an expanding backlog, and a significant defense contract, fueling investor confidence in its transition from a pure launch provider to a vertically integrated space infrastructure platform. The community is actively debating the stock's parabolic trajectory and aggressive institutional accumulation, with bulls highlighting the potential for long-term growth as the broader sector benefits from the anticipation of future IPOs.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is generating significant community conversation as investors speculate on its potential role as a leader in the tokenized real-world assets (RWA) space, particularly following reports of a positive conclusion to its regulatory investigation. While some participants are actively accumulating in anticipation of long-term institutional adoption, others express frustration over price volatility and the impact of scheduled token unlocks.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is surging following record-breaking quarterly financial results that significantly exceeded revenue and earnings expectations, further fueled by a major new customer engagement. The community is actively discussing the potential for a massive short squeeze and long-term valuation repricing, as investors focus on the company's accelerating adoption in the AI data infrastructure sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares have experienced a sharp, multi-day surge driven by the disclosure of early-stage research into an mRNA-based hantavirus vaccine. Investors are aggressively betting on the stock as a potential play on heightened pandemic awareness, with the community actively speculating on the stock's parabolic potential and closely watching for further virus-related news or government updates.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant community enthusiasm following the CME Group's decision to include its futures in their crypto derivatives suite, a move many traders view as a major institutional validation. Investors are actively discussing the token's technical strength compared to other Layer-1 networks, with many focusing on accumulation strategies while keeping a close watch on key resistance levels.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is surging on massive volume as investors weigh its pivot toward governed enterprise AI infrastructure, headlined by a strategic MOU with AMD, against concerns over the company's significant debt load. Community discussion is polarized between bulls betting on a fundamental turnaround and potential short squeeze, and bears warning of imminent share dilution and long-term solvency risks.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors closely monitor the upcoming Senate markup of the Clarity Act, which many believe could remove a significant barrier for institutional adoption. While some community members are frustrated by the token's stagnant price action relative to other major assets, others remain optimistic, pointing to recent real-world integration news and strong ETF inflow data as key indicators of long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Biotech Stocks To Keep An Eye On - December 9th

WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

<ul class="summary-bullets"><li>Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection.</li><li>Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection outcomes.</li><li>The treatment was well tolerated, with no burixafor-related side effects above Grade 2 reported in the study.</li></ul>Shares of Exicure Inc. (XCUR) surged nearly 40% on Tuesday after the company reported encouraging Phase 2 results for its experimental stem cell mobilization drug burixafor (GPC-100).&nbsp;The findings, shared at the American Society of Hematology meeting in Orlando, focused on patients with multiple myeloma preparing for autologous stem cell transplant.<h2 class="st-heading-2">Trial Meets Primary Endpoint</h2>The open-label, multicenter study found that 17 of 19 patients reached the trial’s stem cell collection target within two sessions. Two additional patients reached the target after an extra session.Among participants who proceeded to transplant, median neutrophil engraftment occurred in 13 days and platelet engraftment in 17.5 days. Exicure said burixafor worked quickly, boosting CD34+ stem cells, the cells doctors need to collect for transplant, within about an hour. The company said that the rapid rise makes it possible to give the drug and collect the cells on the same day.<h2 class="st-heading-2">Activity In Daratumumab-Exposed Patients</h2>Sixteen of 19 patients had previously received daratumumab, a therapy linked to reduced stem cell yield. Of these, 14 patients met the primary endpoint, including 12 of 14 who had also been treated with lenalidomide.Longer intervals between the last daratumumab dose and leukapheresis were associated with higher CD34+ cell yields.<h2 class="st-heading-2">Safety Findings</h2>The regimen of burixafor, propranolol, and G-CSF was well tolerated, with no adverse events above Grade 2 attributed to burixafor.“In this Phase 2 study, the combination of burixafor, G-CSF and propranolol showed an excellent safety profile and supported reliable mobilization of hematopoietic progenitor cells,” said lead investigator Jack Khouri of the Cleveland Clinic, adding that rapid cell mobilization may reduce the burden of the process for patients.<h2 class="st-heading-2">Pipeline Expansion Plans</h2>Burixafor, a selective CXCR4 antagonist acquired through Exicure’s January purchase of GPCR Therapeutics’ assets, is also being evaluated in sickle cell disease, rare transplant-eligible disorders, and cell and gene therapy settings.Exicure said a chemosensitization study in acute myeloid leukemia is planned, based on the drug’s ability to mobilize malignant cells from the bone marrow into peripheral blood.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Exicure was ‘extremely bullish’ amid ‘extremely high’ message volume. One user said, “Wow! This candle is showing a strong bullish setup. A powerful pump is coming.”<stembedurl>https://stocktwits.com/OmidArefi/message/638609203</stembedurl><figure class="image"><img style="aspect-ratio:968/141;" src="https://news.stocktwits-cdn.com/xcur_ss_png_95a0e0eba0.webp" alt="xcur ss.png" width="968" height="141"><figcaption>XCUR sentiment and message volume as of December 9| Source: Stocktwits</figcaption></figure>Another user called the stock cheap at the current price, “considering the data!”<stembedurl>https://stocktwits.com/Notoriousinvestor/message/638601332</stembedurl><a href="https://stocktwits.com/symbol/XCUR">Exicure’s stock</a> has declined 45% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exicure’s stock (XCUR) has declined 45% so far in 2025. (Photo credit: Getty Images)

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

Equity

Exicure, Inc. Loss At -$2.44 Mln In Q3

(RTTNews) - Exicure, Inc. (XCUR) reported Loss for third quarter of -$2.44 million...

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest XCUR News

XCURExicure Inc